论文部分内容阅读
目的：探讨氯氮平联合氨磺必利治疗难治性精神分裂症的临床疗效和安全性。方法将64例难治性精神分裂症患者按随机数字表法分为两组，每组32例，两组均服用氯氮平治疗3个月后，研究组在此基础上联合氨磺必利治疗3个月，对照组继续服用氯氮平治疗3个月，观察6个月。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗3个月两组阳性与阴性症状量表评分均较治疗前显著下降（P＜0．01），治疗6个月研究组较治疗3个月仍有显著性下降（P＜0．01），对照组与治疗3个月评分比较差异无显著性（P＞0．05），研究组治疗6个月阳性与阴性症状量表评分显著低于对照组（P＜0．01）。研究组显效率61．3％、总有效率90．3％，对照组分别为32．2％、80．6％，研究组显效率显著高于对照组（χ2＝4．15，P＜0．05），总有效率与对照组比较差异无显著性（χ2＝0．52，P＞0．05）。结论氯氮平联合氨磺必利治疗难治性精神分裂症具有协同增效作用，且不增加不良反应，优于单用氯氮平治疗。“,”Objective To explore the efficacy and safety of clozapine combined with amisulpride in treat‐ment of refractory schizophrenia .Methods Sixty‐four refractory schizophrenia patients were randomly di‐vided into 2 groups of 32 one each ,after 3 month clozapine treatment for both groups research group was plus amisulpride for 3 months ,control group continued clozapine treatment for 3 months ,and they were observed for 6 months .Efficacies were assesses with the Positive and Negative syndrome Scale (PANSS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) . Results At the end of 3 month treatment the PANSS scores of both groups lowered more significantly compared with pre‐treatment (P<0 .01) ,so did that at the end of 6 than of 3 month treatment in research group (P0 .05) ,that was significantly lower at the end of the 6 month treatment in research than in control group (P<0 .01) .Obvious and total effective rate were respectively 61 .3% and 90 .3% in research and 32 .2%and 80 .6% in control group ,obvious effective rate was significantly higher in research than in control group (χ2 =4 .15 ,P0 .05) .Conclusion Amisulpride combined with clozapine has a synergism in the treatment of refractory schizophrenia and doesn’t increase adverse reactions compared with single clozapine treatment .